RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

Otros idiomas Rapid Therapeutic Science Laboratories, Inc.

Acciones

RTSL

US7534312043

Diferido OTC Markets Otros sitios de cotización 18:34:46 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,005 ^USD	0,00 %		0,00 %	+21,95 %

2023	Rapid Therapeutic Science Laboratories, Inc. informa de los resultados del segundo trimestre y de los seis meses finalizados el 30 de junio de 2023	CI
2023	Rapid Therapeutic Science Laboratories, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	06/12
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	30/03/23
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23
Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23
White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	21/03/23
Rapid Therapeutic Science Laboratories Updates Patents	13/12/22
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	10/11/22
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	12/08/22
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review	26/07/22
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)	31/05/22
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	31/05/22
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	11/05/22
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	11/05/22
Rapid Therapeutic Science Laboratories to Attend the Respiratory Drug Delivery (RDD) 2022 Conference	28/04/22
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split	31/03/22
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	16/03/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Rapid Therapeutic Science Laboratories, Inc.

Acciones

RTSL

US7534312043

Otros idiomas

Filtros